CME Group Inc. (NASDAQ:CME) CEO Terrence A. Duffy sold 17,375 shares of the firm’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $112.58, for a total value of $1,956,077.50. Following the transaction, the chief executive officer now owns 127,739 shares in the company, valued at $14,380,856.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
CME Group Inc. (NASDAQ:CME) traded down 0.85% during midday trading on Monday, reaching $111.88. The company’s stock had a trading volume of 1,381,580 shares. The firm has a 50 day moving average price of $106.96 and a 200-day moving average price of $102.74. CME Group Inc. has a 52 week low of $81.87 and a 52 week high of $117.80. The firm has a market cap of $37.97 billion, a P/E ratio of 26.08 and a beta of 0.81.
CME Group (NASDAQ:CME) last posted its quarterly earnings data on Thursday, October 27th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.01. CME Group had a net margin of 41.54% and a return on equity of 6.90%. The company earned $842 million during the quarter, compared to the consensus estimate of $855.94 million. During the same period in the prior year, the business posted $1.02 EPS. The company’s quarterly revenue was down 1.0% on a year-over-year basis. On average, analysts forecast that CME Group Inc. will post $4.35 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 28th. Investors of record on Friday, December 9th will be paid a $0.60 dividend. The ex-dividend date is Wednesday, December 7th. This represents a $2.40 annualized dividend and a yield of 2.15%. CME Group’s dividend payout ratio (DPR) is currently 55.94%.
Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lowered CME Group from an “overweight” rating to a “neutral” rating and set a $116.00 target price on the stock. in a report on Monday, November 14th. They noted that the move was a valuation call. RBC Capital Markets set a $92.00 target price on CME Group and gave the company a “sell” rating in a report on Friday, October 28th. Royal Bank Of Canada cut their target price on CME Group from $97.00 to $92.00 and set an “underperform” rating on the stock in a report on Friday, October 28th. Jefferies Group restated a “buy” rating and set a $118.00 target price on shares of CME Group in a report on Thursday, October 13th. Finally, Deutsche Bank AG raised their target price on CME Group from $115.00 to $116.00 and gave the company a “buy” rating in a report on Wednesday, October 5th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $102.89.
A number of large investors have recently modified their holdings of CME. Bronfman E.L. Rothschild L.P. boosted its position in CME Group by 4.0% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 1,155 shares of the company’s stock valued at $121,000 after buying an additional 44 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CME Group by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,621 shares of the company’s stock valued at $157,000 after buying an additional 1,325 shares in the last quarter. Advisors Preferred LLC bought a new position in CME Group during the third quarter valued at $180,000. Warren Averett Asset Management LLC bought a new position in CME Group during the third quarter valued at $211,000. Finally, Parametrica Management Ltd bought a new position in CME Group during the second quarter valued at $212,000. Institutional investors and hedge funds own 79.55% of the company’s stock.
About CME Group